Tags

Type your tag names separated by a space and hit enter

Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics and neuroimaging.
Clin Chem Lab Med. 2015 Sep 01; 53(10):1495-506.CC

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative disorders, involving progressive loss of the nigro-striatal dopaminergic neurons. Cardinal symptoms including tremors, muscle rigidity, drooping posture, drooping, walking difficulty, and autonomic symptoms appear when a significant number of nigrostriatal dopaminergic neurons have already been destroyed. Hence, reliable biomarkers are needed for early and accurate diagnosis to measure disease progression and response to therapy. We review the current status of protein and small molecule biomarkers involved in oxidative stress, protein aggregation and inflammation etc. which are present in cerebrospinal fluid, human blood, urine or saliva. In recent years, advances in genomics, proteomics, metabolomics, and functional brain imaging techniques have led to new insights into the pathoetiology of PD. Further studies in the novel discovery of PD biomarkers will provide avenues to treat PD patients more effectively with few or no side effects.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25581757

Citation

Ren, Rutong, et al. "Recent Advances in Biomarkers for Parkinson's Disease Focusing On Biochemicals, Omics and Neuroimaging." Clinical Chemistry and Laboratory Medicine, vol. 53, no. 10, 2015, pp. 1495-506.
Ren R, Sun Y, Zhao X, et al. Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics and neuroimaging. Clin Chem Lab Med. 2015;53(10):1495-506.
Ren, R., Sun, Y., Zhao, X., & Pu, X. (2015). Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics and neuroimaging. Clinical Chemistry and Laboratory Medicine, 53(10), 1495-506. https://doi.org/10.1515/cclm-2014-0783
Ren R, et al. Recent Advances in Biomarkers for Parkinson's Disease Focusing On Biochemicals, Omics and Neuroimaging. Clin Chem Lab Med. 2015 Sep 1;53(10):1495-506. PubMed PMID: 25581757.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics and neuroimaging. AU - Ren,Rutong, AU - Sun,Yi, AU - Zhao,Xin, AU - Pu,Xiaoping, PY - 2014/07/30/received PY - 2014/11/20/accepted PY - 2015/1/13/entrez PY - 2015/1/13/pubmed PY - 2016/7/12/medline SP - 1495 EP - 506 JF - Clinical chemistry and laboratory medicine JO - Clin Chem Lab Med VL - 53 IS - 10 N2 - Parkinson's disease (PD) is one of the most common neurodegenerative disorders, involving progressive loss of the nigro-striatal dopaminergic neurons. Cardinal symptoms including tremors, muscle rigidity, drooping posture, drooping, walking difficulty, and autonomic symptoms appear when a significant number of nigrostriatal dopaminergic neurons have already been destroyed. Hence, reliable biomarkers are needed for early and accurate diagnosis to measure disease progression and response to therapy. We review the current status of protein and small molecule biomarkers involved in oxidative stress, protein aggregation and inflammation etc. which are present in cerebrospinal fluid, human blood, urine or saliva. In recent years, advances in genomics, proteomics, metabolomics, and functional brain imaging techniques have led to new insights into the pathoetiology of PD. Further studies in the novel discovery of PD biomarkers will provide avenues to treat PD patients more effectively with few or no side effects. SN - 1437-4331 UR - https://www.unboundmedicine.com/medline/citation/25581757/Recent_advances_in_biomarkers_for_Parkinson's_disease_focusing_on_biochemicals_omics_and_neuroimaging_ L2 - https://www.degruyter.com/document/doi/10.1515/cclm-2014-0783 DB - PRIME DP - Unbound Medicine ER -